



RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

1644

PATENT

Case Docket No. CTLIMM.21CP1C

Date: December 3, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

~~7#5~~

Applicant : Simard et al.
App. No. : 10/026,066
Filed : December 7, 2001
For : EPITOPE SYNCHRONIZATION
IN ANTIGEN PRESENTING
CELLS
Examiner : Unassigned
Group Art Unit : 1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on

December 3, 2002

(Date)

M. T. Morley
Marc T. Morley, Reg. No. 52,051

TRANSMITTAL LETTER

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

RECEIVED
DEC 10 2002
TECH CENTER 1600/2900

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) Information Disclosure Statement.
- (X) Form PTO-1449 listing one hundred and forty-eight (148) references, 13 copies of which are included herewith.
- (X) Return prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

M. T. Morley
Marc T. Morley
Registration No. 52,051
Attorney of Record

CTLIMM.21CP1C



RECEIVED
PATENT
JAN 24 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant	:	Simard et al.)	Group Art Unit: 1644
)	
App. No.	:	10/026,066)	
)	
Filed	:	December 7, 2001)	
)	
For	:	EPITOPE)	
		SYNCHRONIZATION IN)	
		ANTIGEN PRESENTING)	
		CELLS)	
)	
Examiner	:	Unassigned)	

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing one hundred and forty-eight (148) references. One hundred thirty-five (135) of the references listed were of record in a prior application. The above-identified application is a continuation of U.S. Patent Application No. 10/005,905, filed November 7, 2001, which is a continuation-in-part of U.S. Patent Application Nos. 09/561,074, 09/560,465, 09/561,572 and 09/561,571 all filed April 28, 2000. Accordingly, pursuant to 37 C.F.R. § 1.98(d), these references are not enclosed. However, if copies of the references are necessary, they can be provided upon request.

Furthermore, pursuant to 37 C.F.R. § 1.98(a)(2), legible copies of thirteen (13) references that were not submitted in a prior application are enclosed herewith.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R.

Appl. No. : 10/026,066
Filed : December 7, 2001

§ 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/3/02

By: M. T. Morley

Marc T. Morley
Registration No. 52,051
Attorney of Record
2040 Main Street
Fourteenth Floor
Irvine, CA 92614
(619) 235-8550

S:\DOCS\MTM\MTM-3113.DOC\083102

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CTLIMM.21CP1CAPPLICATION NO.
10/026,066INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Simard et al.FILING DATE
December 7, 2001GROUP
1644

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,439,199	03/27/84	Amkraut et al.			
	2.	4,937,190	06/26/90	Palmenberg et al.			
	3.	5,093,242	03/03/92	Bachmair et al.			
	4.	5,132,213	06/21/92	Bachmair et al.			
	5.	5,168,062	12/01/92	Stinski			
	6.	5,258,294	11/02/93	Boyle, et al.			
	7.	5,385,839	01/31/95	Stinski			
	8.	5,478,556	12/26/95	Elliot et al.			
	9.	5,496,721	03/05/96	Bachmair et al.			
	10.	5,580,859	12/03/96	Felgner et al.			
	11.	5,589,466	12/31/96	Felgner et al.			
	12.	5,646,017	07/08/97	Bachmair et al.			
	13.	5,679,647	10/21/97	Carson et al.			
	14.	5,698,396	12/16/97	Pfreundschuh			
	15.	5,733,548	03/31/98	Restifo et al.			
	16.	5,744,316	04/28/98	Lethe et al.			
	17.	5,747,269	05/05/98	Rammensee et al.			
	18.	5,844,075	12/01/98	Kawakami, et al.			
	19.	5,846,540	12/08/98	Restifo et al.			
	20.	5,847,097	12/08/98	Bachmair et al.			
	21.	5,856,187	01/05/99	Restifo et al.			
	22.	5,925,565	07/20/99	Berlioz et al.			
	23.	5,962,428	10/05/99	Carrano et al.			
	24.	5,989,565	11/23/99	Storkus et al.			
	25.	5,993,828	11/30/99	Morton			
	26.	5,994,523	11/30/99	Kawakami et al.			
	27.	6,008,200	12/28/99	Krieg			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard et al.	
		FILING DATE December 7, 2001	GROUP 1644

RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	28.	6,037,135	03/14/00	Kubo et al.		
	29.	6,060,273	05/09/00	Dirks et al.		
	30.	6,287,569	09/11/01	Kipps, et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	31.	74899	08/13/97	Ireland			
	32.	2,147,863	05/26/94	Canada			
	33.	DE 44 23 392 A1	01/11/96	Germany			
	34.	WO 92/01072	12/30/92	PCT			
	35.	EP 1 118 860 A1	07/25/01	EPO			
	36.	WO 92/21033	11/26/92	PCT			
	37.	EP 93/03175	04/06/95	PCT			
	38.	WO 96/01429	01/18/96	PCT			
	39.	WO 96/40209	12/19/96	PCT			
	40.	WO 97/34613	09/25/97	PCT			
	41.	WO 97/41440	11/06/97	PCT			
	42.	WO 98/13489	04/02/98	PCT			
	43.	WO 98/14464	04/09/98	PCT			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	44.	Aki et al., "Interferon- γ Induces Different Subunit Organizations and Functional Diversity of Proteasomes," <i>J. Biochem.</i> , 115: 257-269 (1994)
	45.	Altuvia et al., "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets," <i>Human Immunology</i> , 58: 1-11 (1997)
	46.	Arnold et al., "Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules," <i>Nature</i> , 360: 171-174 (1992)
	47.	Ayyoub, et al., "Lack of tumor recognition by hTERT peptide 540-548-specific CD8 ⁺ T cells from melanoma patients reveals inefficient antigen processing," <i>Eur. J. Immunol.</i> , 31:2642-2651 (2001)
	48.	Bachman et al., "In vitro vs. in vivo assays for the assessment of T-and B cell function," <i>Curr. Opin. Immunol.</i> , 6: 320-326 (1994)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066 RECEIVED
	APPLICANT Simard et al.	DEC 10 2002
	FILING DATE December 7, 2001	GROUP 1644 TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	49. Bettinotti et al., "Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy," <i>J. Immunol.</i> , 161: 877-889 (1998)
	50. Boes et al., "Interferon γ Stimulation Modulates the Proteolytic Activity and Cleavage Site Preference of 20S Mouse Proteasomes," <i>J. Exp. Med.</i> , 179: 901-909 (1994)
	51. Brown et al., "Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes," <i>Nature</i> , 353: 355-357 (1991)
	52. Butterfield et al., "Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus," <i>J. Immunol.</i> , 161: 5607-5613 (1998)
	53. Chattergoon, et al., "Genetic Immunization: a new era in vaccines and immune therapeutics," <i>FASEB J.</i> , 11:753-763 (1997)
	54. Chaux et al., "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1," <i>The Journal of Immunology</i> , 163: 2928-2936 (1999)
	55. Davis, H. L., "Plasmid DNA expression systems for the purpose of immunization," <i>Current Opinion in Immunology</i> , 8: 635-640 (1997)
	56. Dean et al., "Sequence requirements for plasmid nuclear import," <i>Experimental Cell Research</i> , 253: 713-722 (1999)
	57. DeGroot et al., "An Interactive Web Site Providing Major Histocompatibility Ligand Predictions: Application to HIV Research," <i>Aids Res. and Human Retrov.</i> , 13: 529-531 (1997)
	58. Dick et al., "Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands," <i>Cell</i> , 86: 253-262 (1996)
	59. Dick, et al., "Proteolytic Processing of Ovalbumin and β -galactosidase by the Proteasome to Yield Antigenic Peptides," <i>J. of Immunology</i> , 152:3884-3894 (1994)
	60. Driscoll et al., "MHC-linked LMP gene products specifically alter peptidase activities of the proteasome," <i>Nature</i> , 365: 262-264 (1993)
	61. Durrant, L.G., "Cancer vaccines," <i>Anti-cancer drugs</i> , 8: 727-733 (1997)
	62. Farrar et al., "The molecular cell biology of interferon- γ and its receptor," <i>Annu. Rev. Immunol.</i> , 11: 571-611 (1993)
	63. Fiette et al., "Theiler's virus infection of 129Sv mice that lack the interferon α/β or interferon γ receptors," <i>J. Exp. Med.</i> , 181: 2069-2076 (1995)
	64. Gaczynska et al., " γ -Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes," <i>Nature</i> , 365: 264-267 (1993)
	65. Gale et al., "Evidence that hepatitis C Virus resistance to interferon is mediated through repression of the PKR protein kinase by the oncostructural 5A protein," <i>Virology</i> , 230: 217-227 (1997)
	66. Gileadi et al., "Generation of an Immunodominant CTL Epitope is Affected by Proteasome Subunit Composition and Stability of the Antigenic Protein," <i>Am. Assoc. of Immunol.</i> , 163: 6045-6052 (1999)
	67. Glynne et al., "A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC," <i>Nature</i> , 353: 357-360 (1991)
	68. Groettrup et al., "A role for the proteasome regulator PA28a in antigen presentation," <i>Nature</i> , 381: 166-168 (1996)
	69. Gulukota et al., "Two complementary methods for predicting peptides binding major histocompatibility complex molecules," <i>J. Mol. Biol.</i> , 267: 1258-1267 (1997)
	70. Gurunathan et al., "DNA vaccines: a key for inducing long-term cellular immunity," <i>Current Opinion in Immunology</i> , 12: 442-447 (2000)
	71. Heim et al., "Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway," <i>Journal of Virology</i> , 73: 8469-8475 (1999)
	72. Huang et al., "Immune response in mice that lack the interferon- γ receptor," <i>Science</i> , 259: 1742-1745 (1993)
	73. International Search Report from co-pending Application No. PCT/US01/13806
	74. Jager et al., "Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo," <i>Int. J. Cancer</i> , 67: 54-62 (1996)
	75. Jager et al., "Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes," <i>J. Exp. Med.</i> , 187: 265-270 (1998)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066 <div style="text-align: right; font-size: 2em; font-weight: bold;">RECEIVED</div>
	APPLICANT Simard et al.	<div style="text-align: right; font-size: 1.5em;">DEC 10 2002</div>
	FILING DATE December 7, 2001	GROUP 1644 TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	76. Kang et al., "Induction of Melanoma Reactive T Cells by Stimulator Cells Expressing Melanoma Epitope-Major Histocompatibility Complex Class I Fusion Proteins," <i>Cancer Res.</i> , 57: 202-205 (1997)
	77. Kawakami et al., "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>J. Immunother.</i> , 21:237-246 (1998)
	78. Kelly et al., "Second proteasome-related gene in the human MHC class II region," <i>Nature</i> , 353:667-668 (1991)
	79. Kittlesen et al., "Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development," <i>J. Immunol.</i> , 160: 2099-2106 (1998)
	80. Kundig et al., "Fibroblasts as efficient antigen-presenting cells in lymphoid organs," <i>Proc. Natl. Acad. Sci.</i> , 268:1343-1347 (1995)
	81. Kundig et al., "On the role of antigen in maintaining cytotoxic T cell memory," <i>Proc. Natl. Acad. Sci. USA</i> , 93:9716-9723 (1996)
	82. Larregina et al., "Direct Transfection and Activation of Human Cutaneous Dendritic Cells," <i>Gene Ther.</i> , 8:608-617 (2001)
	83. Lee et al., "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients," <i>Nature Medicine</i> , 5:677-685 (1999)
	84. Leitner, et al., "DNA and RNA-based vaccines: principles, progress and prospects," <i>Vaccine</i> , 18:765-777 (2000)
	85. Levy et al., "Using ubiquitin to follow the metabolic fate of a protein," <i>Proc. Natl. Acad. Sci USA</i> , 93: 4907-4912 (1996)
	86. Linette et al., "In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma," <i>J. Immunol.</i> , 164: 3402-3412 (2000)
	87. Loftus et al., "Peptides Derived from Self-Proteins as Partial Agonists and Antagonists of Human CD8+ T-cell Clones Reactive to Melanoma/Melanocyte Epitope MART1(27-35)," <i>Cancer Res.</i> , 11: 2433-2439 (1998)
	88. Maksymowych et al., "Invasion by Salmonella typhimurium Induces Increased Expression of the LMP, MECL, and PA28 Proteasome Genes and Changes in the Peptide Repertoire of HLA-B27," <i>Infection and Immunity</i> , 66:4624-4632 (1998)
	89. Martinez et al., "Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene," <i>Nature</i> , 353:664-667 (1991)
	90. Mateo et al., "An HLA-A2 polyepitope vaccine for melanoma immunotherapy," <i>The Journal of Immunology</i> , 163: 4058-4063 (1999)
	91. McCluskie, et al., "Route and Method of Delivery of DNA Vaccine Influence Immune Response in Mice and Non-Human Primates," <i>Molecular Medicine</i> , 5:287-300 (1999)
	92. Meister et al., "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," <i>Vaccine</i> , 13: 581-591 (1995)
	93. Melief, C. J., <i>Cancerlit</i> , Database Accession No. 1998625858, "Towards T-cell immunotherapy of cancer," Meeting Abstract (1996)
	94. Miconnet et al., "Amino acid identity and/or position determine the proteasomal cleavage of the HLA-A *0201-restricted peptide tumor antigen MAGE-3," <i>The American Society for Biochemistry and Molecular Biology, Inc.</i> , page 20 (2000)
	95. Missale et al., "HLA-A31-and HLA-Aw68-restricted Cytotoxic T cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope during Acute Viral Hepatitis," <i>J. Exp. Med.</i> , 177: 751-762 (1993)
	96. Momburg et al., "Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation," <i>Nature</i> , 360: 174-177 (1992)
	97. Morel et al., "Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells," <i>Immunity</i> , 12: 107-117 (2000)
	98. Moskopidis et al., "Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus," <i>Journal of Virology</i> , 69: 7423-7429 (1995)
	99. Murphy et al., "Higher-Dose and Less Frequent Dendritic Cell Infusions with PSMA Peptides in Hormone-Refractory Metastatic Prostate Cancer Patients," <i>The Prostate</i> , 43: 59-62 (2000)
	100. Noppen et al., "Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2," <i>Int. J. Cancer</i> , 87: 241-246 (2000)
	101. Nussbaum et al., "Cleavage motifs of the yeast 20S proteasome β subunits deduced from digest of enolase 1," <i>Proc. Natl. Acad. Sci USA</i> , 95: 12504-12509 (1998)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard et al.	DEC 10 2002
		FILING DATE December 7, 2001	GROUP 1644


RECEIVED

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	102. Oehen et al., "Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen," <i>J. Exp. Med.</i> 176: 1273-1281 (1992)
	103. Oldstone et al., "Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection," <i>Journal of Virology</i> , 69: 7423-7429 (1995)
	104. Ortiz-Navarrete et al., "Subunit of the '20S proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex," <i>Nature</i> , 353: 662-664 (1991)
	105. Pantaleo et al., "Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection," <i>Proc. Natl. Acad. Sci.</i> , 94: 9848-9853 (1997)
	106. Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>Journal of Immunology</i> , 152: 163 (1994)
	107. Perez-Diez et al., "Generation of CD8+ and CD4+ T-cell Response to Dendritic Cells Genetically Engineered to Express the MART-1/Melan-A Gene," <i>Cancer Res.</i> , 58: 5305-5309 (1998)
	108. Preckel et al., "Impaired Immunoproteasome Assembly and Immune Responses in PA28-I-Mice," <i>Science</i> , 286: 2162-2165 (1999)
	109. Puccetti et al., "Use of skin test assay to determine tumor-specific CD8+ T cell reactivity," <i>Eur. J. Immunol.</i> 24: 1446-1452 (1994)
	110. Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> , 41: 178-228 (1995)
	111. Rammensee et al., "Peptide motifs: amino acids in peptide-MHC interactions," <i>Landes Bioscience Austin Texas</i> , Chapter 4: 217-369 (1997)
	112. Rammensee et al., "SYFPEITHI: Database for MHC ligands and peptide motifs," <i>Immunogenetics</i> , 50: 213-219 (1999)
	113. Raz et al., "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 5141-5145 (1996)
	114. Reeves et al., "Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene," <i>Cancer Res.</i> , 56: 5672-5677 (1996)
	115. Rehmann et al., "The Cytotoxic T Lymphocyte Response to Multiple Hepatitis B Virus Polymerase Epitopes During and After Acute Viral Hepatitis," <i>Journal of Exp. Medicine</i> , 181: 1047-1058 (1995)
	116. Roberts et al., "Prediction of HIV Peptide Epitopes by a Novel Algorithm," <i>Aids Research and Human Retroviruses</i> , 12: 593-610 (1996)
	117. Rock et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides," <i>Annu. Rev. Immunol.</i> , 17: 739-779 (1999)
	118. Roman et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants," <i>Nature Medicine</i> , 3: 849-854 (1997)
	119. Rosmorduc et al., "Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein," <i>Journal of General Virology</i> , 80: 1253-1262 (1999)
	120. Ryan et al., "A model for nonstoichiometric, cotranslational protein scission in eukaryotic ribosomes," <i>Bioorganic Chemistry</i> , 27: 55-79 (1999)
	121. Salmi et al., "Tumor endothelium selectively supports binding of IL-2 propagated tumor-infiltrating lymphocytes," <i>The Journal of Immunology</i> , 154: 6002-6012 (1995)
	122. Sato et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization," <i>Science</i> , 273: 352-354 (1996)
	123. Schirle et al., "Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens," <i>Journal of Immunological Methods</i> , 257: 1-16 (2001)
	124. Schneider, et al., "Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1," <i>Int. J. Cancer</i> , 75(3):451-458 (1998)
	125. Seipelt et al., "The structures of picomaviral proteinases," <i>Virus Research</i> , 62: 159-168 (1999)
	126. Sewell et al., "IFN-γ Exposes a Cryptic Cytotoxic T Lymphocyte Epitope in HIV-1 Reverse Transcriptase," <i>J. Immunol.</i> , 162: 7075-7079 (1999)
	127. Sijts et al., "Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes," <i>Journal of Exp. Medicine</i> , 191: 503-513 (2000)
	128. Speiser et al., "Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy," <i>Journal Exp. Medicine</i> , 186: 645-653 (1997)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLMIM.21CP1C	APPLICATION NO. 10/028,066
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard et al.	DEC 10 2002
		FILING DATE December 7, 2001	GROUP 1644



RECEIVED

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	129. Stauss et al., "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-cell Epitopes in Human Papilloma," <i>Proc. Natl. Acad. Sci.</i> , 89: 7871-7875 (1992)
	130. Steinman et al., "The dendritic cell system and its role in immunogenicity," <i>Annual Review of Immunology</i> , 9: 271-296 (1991)
	131. Stumliolo et al., "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nature Biotechnology</i> , 17: 555-561 (1999)
	132. Taylor et al., "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein," <i>Science</i> , 285: 107-110 (1999)
	133. Thomson et al., "Minimal epitopes expressed in a recombinant polypeptide protein are processed and presented to CD8 ⁺ cytotoxic T cells: Implications for vaccine design," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 5845-5849 (1995)
	134. Tjoa et al., "Evaluation of Phase I/II Clinical Trials in Prostate Cancer with Dendritic Cells and PSMA Peptides," <i>The Prostate</i> , 36: 39-44 (1998)
	135. Twu et al., "Transcription of the human beta interferon gene is inhibited by hepatitis B virus," <i>Journal of Virology</i> , 63: 3065-3071 (1989)
	136. Valmori et al., "Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue," <i>J. Immunol.</i> , 164: 1125-1131 (2000)
	137. Van den Eynde et al., "Differential Processing of Class-I-Restricted Epitopes by the Standard Proteasome and the Immunoproteasome," <i>Curr. Opinion in Immunol.</i> , 13: 147-153 (2001)
	138. Van Kaer et al., "Altered Peptidase and Viral-Specific T Cell Response in LMP2 Mutant Mice," <i>Immunity</i> 1: 533-541 (1994)
	139. Vitiello et al., "Comparison of Cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance," <i>Euro. Jr. Immunol.</i> , 27: 671-678 (1997)
	140. Wang et al., "Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma," <i>Clin. Cancer Res.</i> , 10: 2756-2765 (1999)
	141. Yang et al., "Proteasomes Are Regulated By Interferon γ : Implications For Antigen Processing," <i>Proc. Natl. Acad. Sci.</i> , 89: 4928-4932 (1992)
	142. Yewedell, et al., "MHC-Encoded Proteasome Subunits LMP2 and LMP7 Are Not Required for Efficient Antigen Presentation," <i>J. Immunology</i> 1994, 152:1163-1170 (1994)
	143. Young et al., "Dendritic Cells As Adjuvants For Class I Major Histocompatibility Complex-Restricted Antitumor Immunity," <i>J. Exp. Med.</i> , 183: 7-11 (1996)
	144. Zajac et al., "Enhanced Generation of Cytotoxic T Lymphocytes Using Recombinant Vaccinia Virus Expressing Human Tumor-Associated Antigens and B7 Costimulatory Molecules," <i>Cancer Res.</i> , 58: 4567-4571 (1998)
	145. Zajac et al., "Generation of Tumoricidal Cytotoxic T Lymphocytes from Healthy Donors after In Vitro Stimulation with a Replication-Incompetent Vaccinia Virus Encoding MART-1/Melan-A 27-35 Epitope," <i>Int. J. Cancer</i> , 71: 491-496 (1997)
	146. Zhai et al., "Antigen-Specific Tumor Vaccines. Development and Characterization of Recombinant Adenoviruses Encoding MART1 or gp100 for Cancer Therapy," <i>J. Immunol.</i> , 156: 700-710 (1996)
	147. Zipkin, I., "Cancer vaccines," <i>Bio Century</i> , 6: A1-A6 (1998)
	148. NCBI Blast Accession Number NP_005502

S:\DOCS\MTM\MTM-3114.DOC\083102

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	